Cost-effectiveness analysis of influenza and pneumococcal vaccination for Hong Kong elderly in long-term care facilities

Journal of Epidemiology and Community Health

Volumn 63, Issue 11, 2009, Pages 906-911

  You, J H S ^a   Wong, W C W ^b   Ip, M ^c   Lee, N L S ^c   Ho, S C ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE;

COST-BENEFIT ANALYSIS; ELDERLY POPULATION; HEALTH SERVICES; INFLUENZA; MONTE CARLO ANALYSIS; PUBLIC HEALTH; STATISTICAL ANALYSIS; VACCINATION;

AGED; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE COST; HEALTH CARE FACILITY; HONG KONG; HUMAN; INFLUENZA; INFLUENZA VACCINATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PNEUMOCOCCAL INFECTION; QUALITY ADJUSTED LIFE YEAR; UNSPECIFIED SIDE EFFECT;

AGED; COST-BENEFIT ANALYSIS; FEMALE; HOMES FOR THE AGED; HONG KONG; HOSPITALIZATION; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; LONG-TERM CARE; MALE; MARKOV CHAINS; MODELS, ECONOMIC; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; QUALITY-ADJUSTED LIFE YEARS; STATE MEDICINE; VACCINES, COMBINED;

ASIA; CHINA; EURASIA; FAR EAST; HONG KONG;

EID: 70350230262     PISSN: 0143005X     EISSN: 14702738     Source Type: Journal    
DOI: 10.1136/jech.2008.081885     Document Type: Article

References (35)

1. The Government of Hong Kong SAR. www.gov.hk.
2. Nichol KL, Margolis KL, Wuorenma J, et al. The efficacy and cost-effectiveness of vaccination against influenza among elderly persons living in the community. N Eng J Med 1994;331:778-784 (Pubitemid 24284768)
3. Nordin J, Mullooly J, Poblete S, et al. Influenza vaccine effectiveness in preventing hospitalizations and deaths in person 65 years or older in Minnesota, New York, and Oregon: data from 3 health plans. J Infect Dis 2001;184:665-670 (Pubitemid 32826416)
4. Jackson LA, Neuzil KM, Yu O, et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Eng J Med 2003;348:1747-1755 (Pubitemid 36514705)
5. Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2002;51(RR-3):1-31.
6. Centers for Disease Control and Prevention. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1997;46(RR-8):1-24.
7. Mullooly JP, Bennett MD, Hornbrook MC, et al. Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization. Ann Intern Med 1994;121:947-952
8. Lee N, Chan PKS, Cho KW, et al. Factors associated with early hospital discharge of adult influenza patients. Antiviral Therapy 2007;12:501-508 (Pubitemid 47041148)
9. Sisk JE, Moskowitz AJ, Whang W, et al. Cost-effectiveness of vaccination against pneumococcal bacteremia among elderly people. JAMA 1997;278:1333-1339 (Pubitemid 27449693)
10. Jackson LA, Jackson ML, Nelson JC, et al. Evidence of bias in estimates of influenza vaccine effectiveness in seniors. Int J Epidemiol 2006;35:337-344
11. Jackson LA, Nelson JC, Benson P, et al. Functional status is a confounder of the association of influenza vaccine and risk of all cause mortality in seniors. Int J Epidemiol 2006;35:345-352
12. Rivetti D, Jefferson T, Thomas R, et al. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev 2007;3.
13. Drummond MF, Sculpher MJ, Torrance GW, et al., eds. Methods for the economic evaluation of health care programmes, 3rd edn. Oxford: Oxford University Press, 2005.
14. Sonnenberg FA, Beck RJ. Markov models in medical decision making: a practice guide. Med Decis Making 1993;13:322-338
15. Man SY, Lee N, Ip M, et al. Prospective comparison of three predictive rules for assessing severity of community-acquired pneumonia in Hong Kong. Thorax 2007;62:348-353 (Pubitemid 46580578)
16. Nuijten MJC. The selection of data sources for use in modelling studies. Pharmacoeconomics 1998;13:305-316 (Pubitemid 28123370)
17. Moberley SA, Holden J, Tatham DP, et al. Vaccine for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2008;2. (Pubitemid 351807720)
18. Christenson B, Hedlund J, Lundbergh P, et al. Additive preventive effect of influenza and pneumococcal vaccines in elderly persons. Eur Respir J 2004;23:363-368 (Pubitemid 38351093)
19. Nichol KL, MacDonald R, Hauge M. Side effects associated with pneumococcal vaccination. Am J Infect Control 1997;25:223-228 (Pubitemid 27274684)
20. Chen YH, Liou SH, Chou CC, et al. Influenza and pneumococcal vaccination of the elderly in Taiwan. Vaccine 2004;22:2806-2811 (Pubitemid 38900658)
21. Erickson P, Wilson R, Shannon I. Years of healthy life. Stat Notes 1995;7:1-14.
22. Centers for Medicare and Medicaid Services website. http://www.cms.hhs. gov (accessed 22 Jan 2009).
23. Aballea S, Chancellor J, Martin M, et al. The cost-effectiveness of influenza vaccination for people aged 50-64 years: an international model. Value Health 2007;10:98-116. (Pubitemid 46481137)
24. Hoshi SL, Kondo Masahide, Honda Y, et al. Cost-effectiveness analysis of influenza vaccination for people aged 65 and over in Japan. Vaccine 2007;25:6511-6521 (Pubitemid 47198918)
25. Nichol KL, Goodman M. Cost effectiveness of influenza vaccination for healthy person between ages 65 and 74 years. Vaccine 2002;20(Suppl 2):S21-4. (Pubitemid 34756338)
26. Maucher JM, Gamber SR. Cost-effective analysis of influenza vaccination in the elderly. Age 1990;13:81-85
27. Patriarca PA, Arden NH, Koplan JP, et al. Prevention and control of type A influenza infections in nursing homes. Benefits and costs of four approaches using vaccination and amantadine. Ann Intern Med 1987;107:732-740
28. Wang CS, Wang ST, Chou P. Efficacy and cost-effectiveness of influenza vaccination of the elderly in a densely populated and unvaccinated community. Vaccine 2002;20:2494-2499 (Pubitemid 34615587)
29. Nichol KL, Wuorenma J, von Sternberg T. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Arch Intern Med 1998;158:1769-1776 (Pubitemid 28421420)
30. Davis JW, Lee E, Taira DA, et al. Influenza vaccination, hospitalization, and costs among members of a Medicare managed care plan. Med Care 2001;39:1273-1280 (Pubitemid 33603671)
31. Gasparini R, Lucioni C, Lai P, et al. Cost-benefit evaluation of influenza vaccination in the elderly in the Italian region of Liguria. Vaccine 2002;20:B50-4. (Pubitemid 35435399)
32. Chen YH, Yang GY, Loh CH, et al. Cost benefits of targeting the pneumococcal vaccination program to the elderly population in Taiwan. Am J Infect Control 2006;34:597-599
33. Mangtani P, Roberts JA, Hall AJ, et al. An economic analysis of a pneumococcal vaccine programme in people aged over 64 years in a developed country setting. Int J Epidemiol 2005;34:565-574 (Pubitemid 40852570)
34. Postma MJ, Heijnen MLA, Jager JC. Cost-effectiveness analysis of pneumococcal vaccination for elderly individuals in the Netherlands. Pharmacoeconomics 2001;19:215-222
35. Cai L, Uchiyama H, Yanagisawa S, et al. Cost-effectiveness analysis of influenza and pneumococcal vaccinations among elderly people in Japan. Kobe J Med Sci 2006;52:97-100. (Pubitemid 44338394)